Carros, France, April 16, 2025 - Virbac, a global leader in animal health, announces it has licensed novel therapeutic antibodies from MabGenesis, a private biopharmaceutical company headquartered in Yokohama, Japan.

Under the agreement, Virbac has the right to develop and commercialize products using the novel monoclonal antibodies for potential canine therapeutic treatments. MabGenesis will receive license fees as well as milestone payments based on the stage of development and certain royalty for the sales of the product.

“This agreement will enable us to offer a technologically advanced solution, which will strengthen the veterinary arsenal and bring significant benefits to both animals and pet owners. We look forward to bringing this innovative solution to market, once the development cycle is complete,”  said Christian Burkhardt, Virbac’s corporate Business Development director.

“We are excited to partner with global animal health leader Virbac as we believe that this license for our assets will bring innovation to animal health through Virbac’s expertise,” said Katsuhiro Shinjo, DVM, PhD, chief executive officer of MabGenesis. “We look forward to continuing our partnership to lead to development of innovative therapeutic antibodies bringing benefits to animal health.”

About MabGenesis Inc.
MabGenesis is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate 100% species-specific monoclonal antibodies rapidly and efficiently. MabGenesis is a private company headquartered in Yokohama, Japan. For more information, visit https://mabgenesis.com/en